Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2
Active, not recruiting · NCT05152914 · Registry updated 2026-04-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Neuronal Ceroid-Lipofuscinoses, Nutritional and Metabolic Diseases, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, lysosomal lipid storage disorder, metabolic disease, nervous system disorder, neurodegenerative disease, neuronal ceroid lipofuscinosis 2 | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-30 | NCT05152914 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| David L Rogers, MD | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nationwide Children's Hospital | Columbus | United States | 309 |